Servier picks Shire executive to run U.S. business being built out of deal for Shire’s oncology unit

Breast Cancer Cells
Servier is establishing its U.S. beachhead in Boston after its $2.4 billion deal to buy Shire’s oncology business. (National Cancer Institute)

Having established a U.S. beachhead with its $2.4 billion deal for Shire’s oncology business, Servier says it has found just the right person to oversee it: Shire executive David K. Lee.

The French company today said Lee will head Servier Pharmaceuticals U.S., a subsidiary it established with its April deal for the Shire operation. He will take on his new job when the deal closes this quarter and will report to Olivier Laureau, president of Servier group, the company said.

Lee is currently head of Shire’s Global Genetic Diseases and Oncology franchises and oversaw the oncology franchise at Baxalta before Shire acquired it. While getting Servier all set up for business in the U.S., he will oversee the Boston-based unit that already has one cancer product in the market, Oncaspar.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: With Takeda still eyeing a buy, Shire casts off oncology drugs for $2.4B

Shire’s spinoff of its nascent oncology operation came just days ahead of its own agreement to be acquired by Takeda for $64 billion, one of the biggest pharma M&A moves in years, and one it said serves its global ambitions. But Servier has an expansive vision of its own.

The French drugmaker today reiterated that the acquisition enables it “to establish an immediate and direct commercial presence in the U.S.” and furthers its ambition to become a global biopharmaceutical company.

Read more on

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.